FX 005

Drug Profile

FX 005

Alternative Names: FX-005

Latest Information Update: 14 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer Flexion Therapeutics
  • Class Analgesics
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Musculoskeletal pain

Most Recent Events

  • 10 Mar 2017 Discontinued - Phase-I/II for Musculoskeletal pain in Spain, Austria, Canada and United Kingdom (Intra-articular)
  • 25 Sep 2015 FX 005 is still in phase-I/II development for Musculoskeletal pain in Austria, Canada, Spain and the United Kingdom
  • 30 May 2012 Interim efficacy and adverse events data from a phase I/II trial in Musculoskeletal pain released by Flexion Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top